All In Biotech

Drug Trial Radar · NCT04896008

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

173

Actual

Start

Dec 1, 2021

Primary completion

Jul 26, 2024

Study completion Feb 18, 2025

Sponsor

Sponsor type
Industry
First posted
May 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension \[PAH\] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • SotaterceptDrug

    SC injection

  • PlaceboOther

    Placebo-matched SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Confirmed Morbidity or Mortality EventTime frame: Up to approximately 31 months

Locations

57 sites in 12 countries. Site status is shown where the registry gives one.

  • Arizona Pulmonary Specialists ( Site 1010)

    Phoenix, Arizona

  • David Geffen School of Medicine at UCLA ( Site 1068)

    Los Angeles, California

  • University of California Irvine ( Site 1086)

    Orange, California

  • University of California San Diego Medical Center ( Site 1002)

    San Diego, California

  • University of California San Francisco ( Site 1019)

    San Francisco, California

  • University of Colorado Hospital ( Site 1013)

    Aurora, Colorado

  • The George Washington University Medical Faculty Associates ( Site 1025)

    Washington D.C., District of Columbia

  • Mayo Clinic Jacksonville - PPDS ( Site 1045)

    Jacksonville, Florida

  • AdventHealth Medical Group Advanced Lung Disease ( Site 1058)

    Orlando, Florida

  • Northside Hospital ( Site 1073)

    Atlanta, Georgia

  • University Of Iowa Hospitals and Clinics ( Site 1050)

    Iowa City, Iowa

  • University of Kansas Medical Center ( Site 1020)

    Kansas City, Kansas

  • Tufts Medical Center - PPDS ( Site 1012)

    Boston, Massachusetts

  • Brigham and Women's Hospital ( Site 1014)

    Boston, Massachusetts

  • University of Michigan ( Site 1011)

    Ann Arbor, Michigan

  • Washington University School of Medicine ( Site 1022)

    St Louis, Missouri

  • University of Nebraska Medical Center ( Site 1053)

    Omaha, Nebraska

  • University of New Mexico Health Sciences Center ( Site 1048)

    Albuquerque, New Mexico

  • University of Rochester Medical Center - PPDS ( Site 1039)

    Rochester, New York

  • Duke University Medical Center ( Site 1026)

    Durham, North Carolina

  • University of Cincinnati Medical Center ( Site 1035)

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation. ( Site 1065)

    Cleveland, Ohio

  • Medical University of South Carolina - PPDS ( Site 1003)

    Charleston, South Carolina

  • Statcare Pulmonary Consultants - Knoxville ( Site 1031)

    Knoxville, Tennessee

  • University Of Texas Southwestern Medical Center ( Site 1038)

    Dallas, Texas

  • Medical College of Wisconsin - Froedtert Hospital ( Site 1051)

    Milwaukee, Wisconsin

  • St Vincent's Hospital Sydney ( Site 1102)

    Darlinghurst, New South Wales, Australia

  • John Hunter Hospital ( Site 1101)

    New Lambton Heights, New South Wales, Australia

  • Hôpital Erasme ( Site 1402)

    Anderlecht, Bruxelles-Capitale, Region de, Belgium

  • UZ Leuven Campus Gasthuisberg ( Site 1401)

    Leuven, Vlaams-Brabant, Belgium

  • Peter Lougheed Centre ( Site 2102)

    Calgary, Alberta, Canada

  • Jewish General Hospital ( Site 2103)

    Montreal, Quebec, Canada

  • Hôpitaux Universitaires de Strasbourg ( Site 1307)

    Strasbourg, Bas-Rhin, France

  • Centre Hospitalier Universitaire de Toulouse. ( Site 1315)

    Toulouse, Haute-Garonne, France

  • CHU de Nancy - Hôpital de Brabois Adultes ( Site 1308)

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

  • CHRU Lille ( Site 1306)

    Lille, Nord, France

  • Hôpital Louis Pradel ( Site 1317)

    Bron, Rhone, France

  • CHU Bicêtre ( Site 1304)

    Le Kremlin-Bicêtre, Val-de-Marne, France

  • CHU de Poitiers ( Site 1316)

    Poitiers, Vienne, France

  • Thoraxklinik-Heidelberg gGmbH ( Site 1509)

    Heidelberg, Baden-Wurttemberg, Germany

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.